SLGL Sol-Gel Technologies Ltd

UPDATE -- Sol-Gel Technologies to Present at Upcoming 2020 Solebury Trout Virtual Investor Conference

UPDATE -- Sol-Gel Technologies to Present at Upcoming 2020 Solebury Trout Virtual Investor Conference

NESS ZIONA, Israel, March 25, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced plans to present an overview of the Company and provide a business update at the upcoming Solebury Trout Virtual Investor Conference. The 25 minute presentation includes an interactive Q&A with participants prompted to submit questions electronically. Details are as follows:

Date: Thursday, March 26, 2020 at 10:30am EDT

Access:

A replay of the webcast will be available 24 hours following the presentation on the Company’s website at

About Sol-Gel Technologies

Sol-Gel is a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Sol-Gel leverages its proprietary microencapsulation technology platform for Twyneo, for the treatment of acne vulgaris, and Epsolay, for the treatment of papulopustular rosacea. The Company’s pipeline also includes SGT-210, an early-stage topical epidermal growth factor receptor inhibitor, erlotinib, for the treatment of punctate palmoplantar keratoderma, and preclinical assets tapinarof and roflumilast. For additional information, please visit .

For further information, please contact:

Sol-Gel Contact:

Gilad Mamlok

Chief Financial Officer

Investor Contact:

Chiara Russo

Solebury Trout



Source: Sol-Gel Technologies Ltd.

EN
25/03/2020

Underlying

SLGLSol-Gel Technologies Ltd

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Sol-Gel Technologies Ltd

 PRESS RELEASE
Free
SLGL Sol-Gel Technol...

Sol-Gel Announces Reverse Share Split

Sol-Gel Announces Reverse Share Split NESS ZIONA, Israel, May 01, 2025 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (the “Company”) (NASDAQ: SLGL), a clinical-stage dermatology company, today announced a reverse share split (the “Reverse Split”) of the Company’s issued and outstanding ordinary shares, par value NIS 0.1 per share (the “Ordinary Shares”), at the ratio of 10-for-1, such that each ten (10) Ordinary Shares shall be consolidated into one (1) Ordinary Share. The Company obtained shareholders’ approval for the Reverse Split at a ratio of between 2:1 and 10:1 at a special meetin...

7h / 49m 1 EN
 PRESS RELEASE
Free
SLGL Sol-Gel Technol...

Sol-Gel and Mayne Pharma Announce the Purchase of EPSOLAY® and TWYNEO®...

Sol-Gel and Mayne Pharma Announce the Purchase of EPSOLAY® and TWYNEO® in the U.S. Sol-Gel to receive $16 million during 2025Cash runway is expected to extend into the first quarter of 2027; Company expects to have sufficient cash to complete its Phase III clinical trialSGT-610 Phase III clinical trial top-line results are expected in the fourth quarter of 2026; a significant milestone in the clinical trial of recruiting more than 80% of the patients has been achievedSol-Gel now estimates the U.S. market potential for SGT-610 to be between $400 to $500 million annuallySGT-210 Phase 1b trial...

April 17, 2025 1 EN
 PRESS RELEASE
Free
SLGL Sol-Gel Technol...

Sol-Gel Announces 180-Day Extension to Regain Compliance with Nasdaq M...

Sol-Gel Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Requirement NESS ZIONA, Israel, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with severe skin conditions, conducting a Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, and with two approved large-category dermatology products, TWYNEO® and EPSOLAY®, today announced that it has received an extension of the period to regain compliance with The Nasdaq Stock Market LLC’s ("Nasdaq") minimum bid price ...

November 20, 2024 1 EN
 PRESS RELEASE
Free
SLGL Sol-Gel Technol...

Sol-Gel Reports Third Quarter 2024 Financial Results and Provides Corp...

Sol-Gel Reports Third Quarter 2024 Financial Results and Provides Corporate Updates Mori Arkin's appointment as interim CEO as of January 1, 2025 approved by shareholdersPhase 3 clinical trial of SGT-610 for Gorlin Syndrome is ongoing with over 40 clinical sites activatedSGT-210 proof-of-concept study in patients suffering from Darier disease is ongoing NESS ZIONA, Israel, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with severe skin conditions, conducting a Phase-3 clinical trial of SGT-610 (pati...

November 15, 2024 1 EN
 PRESS RELEASE
Free
SLGL Sol-Gel Technol...

Sol-Gel Reports Second Quarter 2024 Financial Results and Provides Cor...

Sol-Gel Reports Second Quarter 2024 Financial Results and Provides Corporate Updates Following recent transactions and cost-cutting efforts, Sol-Gel’s cash runway is expected to extend into the first quarter of 2026Ongoing Phase 3 clinical trial of SGT-610 for Gorlin Syndrome with over 30 clinical sites activated; Top-line results are expected by the second quarter of 2026SGT-210 proof-of-concept study in patients suffering from Darier disease, a significant unmet medical need in dermatology, is ongoingSol-Gel sells its rights in the Abbreviated New Drug Application (ANDA)drug product gener...

August 16, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch